XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Formulation business grew by 15 per cent in the quarter
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Subscribe To Our Newsletter & Stay Updated
